Andy Chen

Faisal Khurshid

Jeet Mukherjee

Marc Frahm

Bradley Canino

Eliana Merle

Eric Joseph

Jeffrey Jones

Kalpit Patel

Kelly Shi

Michael Schmidt

Paul Jeng

Sudan Loganathan

Alexei Siniakov

Alex Thompson

Andrea Newkirk

Derek Archila

Dingding Shi

Ellie Merle

Eric Wong

Eva Fortea-Verdejo

Gospel Enyindah-Asonye

Jeff Jones

Judah Frommer

Kripa Devarakonda

Mayank Mamtani

Parth Patel

Ron Feiner

Sam Slutsky

Srikripa Devarakonda

Tazeen Ahmad

Vikram Purohit

- Kymera Therapeutics is actively advancing its **STAT6 program (KT-621)**, having shared positive Healthy Volunteer Study results in **early June 2025** and expecting Phase 1B data in the **fourth quarter of 2025**. The Phase 2B study in atopic dermatitis is anticipated to begin shortly.  **[1815442_2144639_0]** 
- The company's **IRF5 program** is on track, with trials projected to start in **early 2026** and data expected later that year. Kymera also aims to introduce **at least one new program per year**.  **[1815442_2144639_0]** 
- Kymera exited **July 2025** with approximately **$1 billion on its balance sheet**, providing a cash runway **into the second half of 2028**. This funding covers all disclosed programs, including the STAT6 Phase 2B studies and the IRF5 Phase 1.  **[1815442_2144639_0]** 
- The IRAK4 program, in partnership with Sanofi, is progressing with a **second-generation degrader (KT-485)**, which is positioned to enter Phase 1 in **2026**. The company also has potential milestones of just under **$1 billion from Sanofi** and **$750 million from Gilead**.  **[1815442_2144639_6]**

Kymera Therapeutics Updates on Pipeline and Financial Outlook

- Kymera Therapeutics (KYMR) is advancing its **targeted protein degradation (TPD)** platform, focusing on **immunology** to develop oral drugs with biologic-like activity for previously undruggable targets.  **[1815442_tx_380168_0]** 
- The lead program, **KT-621 (STAT6 degrader)**, a first-in-class oral drug, demonstrated **90% or more STAT6 degradation** in Phase 1 and is progressing to **Phase 2b studies for atopic dermatitis in Q4 2025 and asthma in 2026**.  **[1815442_tx_380168_2]** 
- Kymera anticipates KT-621 could become a **first-line oral treatment for millions of Th2 patients**, addressing current access and reimbursement challenges with injectable biologics.  **[1815442_tx_380168_6]** 
- The company's pipeline also includes a **second-generation IRAK4 degrader (KT-485)**, with Sanofi expected to initiate Phase 1 in 2026, and an **IRAK5 degrader** for lupus and IBDRA.  **[1815442_tx_380168_8]** **[1815442_tx_380168_9]** 
- Kymera is already planning **Phase 3 manufacturing and commercialization** for KT-621, reflecting confidence in its market potential.  **[1815442_tx_380168_8]**

Kymera Therapeutics discusses targeted protein degradation platform and pipeline advancements